Description: "The National Cancer Act of 1971 propelled the War on Cancer, mainly by tapping the vast resources of the Federal government to confront the growing cancer challenge. Yet, while some predicted the conquest of cancer by the nation’s bicentennial, it remains a largely incurable disease. After reviewing the history of cancer and its impact on the population, the book exposes the antiquated notions that drive cancer drug development, documents the stagnation in treatment outcomes despite major advances in cancer genomics and growing National Cancer Institute budgets, and reveals the multiple factors that sustain the status quo. It shows that, contrary to frequent announcements of breakthroughs, our current cancer control model cannot eradicate most cancers and the reasons why. The book also delineates a way forward via a shift from the discredited cell-kill approach of the past to an integrated, evidence-driven cancer control paradigm based on prevention, early diagnosis, and pharmacogenomics". Read online: TOC, Preface & Conclusions Publisher: Springer Best prices Hardcover - ISBN-13: 978-1402036187, Pub Date: Nov 2005 Best prices Softcover - ISBN-13: 978-1402086205, Pub Date: Apr 2008 Download Kindle version |
"I am quite impressed with the scope of the effort, the excellent writing, and the sharp and accurate critique over a broad area of modern oncology practice and research. Frankly, I am not aware of many scientists who could synthesize both the basic and clinical material, and lucidly depict the implications in such a compelling manner". Neil Caporaso, M.D. Chief, Pharmacogenetics Section, Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics National Cancer Institute, MD "Dr Faguet's approach is not unlike an analysis of the so-called industrial-military complex.…a complex consisting of the federal government, pharmaceutical drug companies and academia—all have a part of the pie and therefore a reason for maintaining the status quo. Insurance companies, regulatory agencies such as the FDA, and patients themselves add further layers of complexity. Faguet walks through all of these areas in a critical but unemotional manner... His book should be of interest to policy-makers, cancer-care workers, and the public at large". Gerald E. Marti, M.D, Ph.D. Chief, Flow and Image Cytometry Section, Laboratory of Stem Cell Biology National Institutes of Health, MD "I think (Faguet's) book will be a valuable corrective to much of the hype that has been splashed around in greater and greater quantities by the cancer establishment as it tries to stifle the message that it has failed to make much of an impact" John C. Bailar, M.D., Ph.D. Former Deputy Associate Director for Cancer Control, National Cancer Institute, MD Former Editor-in-Chief of the Journal of the National Cancer Institute, MD Professor Emeritus, University of Chicago, IL "The War on cancer is a trenchant and provocative book that offers a critical view of the last four decades in the field of oncology and a vision for the future. To the mainstream oncology community, I would commend it as a challenging treatise" Book review: JAMA 2006;295:2891-2892. Randall Hughes, M.D. Associate Professor The University of Texas Southwestern Medical Center, Dallas, TX “The author should be commended for the broad scope of this book. He masterfully explains advanced biomedical concepts, but also provides ample guideposts for the more advanced reader to skip these explanations and seamlessly follow his overarching narrative. A review of the footnotes shows that he has thorough command of recently published research, his primary source of evidence. The book should be of interest to clinical oncologists, or others interested in an informed critique of cancer research and treatment written by a peer.“ Book Review: The Lancet Oncology, Vol 8 Issue 1, January 2007. Gretchen M. Krueger, MD Johns Hopkins University, Baltimore, MD |
 | |  | |  | |  | |  | |  | |  | |  | |  |